The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you ...

Peter H. Gilligan, Ph.D., D(ABMM) emeritus and F(AAM) was a medical microbiologist at UNC Health for 35 years. Here, he ...

“Our data suggest that microbiota-targeted interventions could mitigate the detrimental effects of early-life antibiotics on ...

Immunization programs save millions of lives every year by protecting against preventable diseases. The immune response to ...

Three years after the start of the COVID-19 pandemic, coverage for selected routine childhood vaccines remained below prepandemic levels.

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Vaxcyte, Inc.'s positive phase 2 results for VAX-24 show promise in preventing invasive pneumococcal disease in infants.

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...

Meanwhile, the launch of new-generation innovative products, including the serum-free rabies vaccine, the 13-valent ...

Meanwhile, the launch of new-generation innovative products, including the serum-free rabies vaccine, the 13-valent pneumococcal conjugate vaccine, the quadrivalent meningococcal conjugate vaccine, as ...

Vaxcyte Inc. characterized its latest phase II data with VAX-24 as positive but Wall Street wasn’t so sure about the dose-finding outcomes with the 24-valent pneumococcal conjugate vaccine (PCV), and ...